1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Kabi Commits To Biosimilars Development

 
• By Aidan Fry

Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.

Kabil
Attendees of the official inauguration of Fresenius Kabi's biosimilars research and development center in Eysins, Switzerland, included the company's CEO, Mats Henriksson (third left) • Source: Fresenius Kabi

Fresenius Kabi said it was committed to developing and marketing biosimilars, especially for autoimmune and oncology indications, as the injectables and infusion specialist inaugurated a biosimilars research and development center that its Fresenius Kabi SwissBioSim unit has built in Eysins, Switzerland. The German company recently took its first commercial step into the biosimilars arena by rolling out its Idacio adalimumab brand in several European countries.

Kabi said the center, in which the firm invested about €15m ($16m), would “intensify biosimilars research and development in the areas of autoimmune diseases and oncology, where the company is...

More from Biosimilars

UK-EU Deal ‘Must Include Medicines, Not Just Sausages,’ Urges Medicines UK

 
• By Urtė Fultinavičiūtė

The UK struck three international agreements in May, but two of them failed to include medicines or provide any benefits for the pharmaceutical sector. Medicines UK warned that protecting medicine supplies should be of the same importance as defense.

Sandoz Leads Charge With First US Denosumab Launch

 
• By Dave Wallace

Competition to Amgen’s Prolia and Xgeva denosumab brands has hit the US market, with Sandoz taking the lead by launching its interchangeable Jubbonti and Wyost biosimilars.

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By Dean Rudge

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.

More from Products

Sandoz Leads Charge With First US Denosumab Launch

 
• By Dave Wallace

Competition to Amgen’s Prolia and Xgeva denosumab brands has hit the US market, with Sandoz taking the lead by launching its interchangeable Jubbonti and Wyost biosimilars.

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By Dean Rudge

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

Trump-Trimmed FDA Finally Releases A Batch Of PSGs – Back To Business As Usual?

 
• By Urtė Fultinavičiūtė

After half a year of silence, the US FDA has published 48 product-specific guidances for generic development. With critical staff laid off, will the health agency stick to its updated PSG publishing schedule?